Találati lista | Tudóstér

001-es BibID:	BIBFORM068910
035-os BibID:	(cikkazonosító)e0162866 (WOS)000383723700018 (Scopus)84992409620
Első szerző:	Mizzi, Clint
Cím:	A European Spectrum of Pharmacogenomic Biomarkers : implications for Clinical Pharmacogenomics / Mizzi Clint, Dalabira Eleni, Kumuthini Judit, Dzimiri Nduna, Balogh Istvan, Başak Nazli, Böhm Ruwen, Borg Joseph, Borgiani Paola, Bozina Nada, Bruckmueller Henrike, Burzynska Beata, Carracedo Angel, Cascorbi Ingolf, Deltas Constantinos, Dolzan Vita, Fenech Anthony, Grech Godfrey, Kasiulevicius Vytautas, Kádaši Ludevít, Kučinskas Vaidutis, Khusnutdinova Elza, Loukas Yiannis L., Macek Milan, Makukh Halyna, Mathijssen Ron, Mitropoulos Konstantinos, Mitropoulou Christina, Novelli Giuseppe, Papantoni Ioanna, Pavlovic Sonja, Saglio Giuseppe, Setric Jadranka, Stojiljkovic Maja, Stubbs Andrew P., Squassina Alessio, Torres Maria, Turnovec Marek, van Schaik Ron H., Voskarides Konstantinos, Wakil Salma M., Werk Anneke, del Zompo Maria, Zukic Branka, Katsila Theodora, Lee Ming Ta Michael, Motsinger-Rief Alison, Mc Leod Howard L., van der Spek Peter J., Patrinos George P.
Dátum:	2016
ISSN:	1932-6203
Megjegyzések:	Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicitywith the underlying genetic composition, particularly in genes encoding for protein factorsand enzymes involved in drug metabolism and transport. In several Europeanpopulations, particularly in countries with lower income, information related to the prevalenceof pharmacogenomic biomarkers is incomplete or lacking. Here, we have implementedthe microattribution approach to assess the pharmacogenomic biomarkers allelicspectrum in 18 European populations, mostly from developing European countries, by analyzing1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant interpopulationpharmacogenomic biomarker allele frequency differences, particularly in 7 clinicallyactionable pharmacogenomic biomarkers in 7 European populations, affecting drugefficacy and/or toxicity of 51 medication treatment modalities. These data also reflect on thedifferences observed in the prevalence of high-risk genotypes in these populations, as faras common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMTpharmacogenes are concerned. Also, our data demonstrate notable differences in predictedgenotype-based warfarin dosing among these populations. Our findings can beexploited not only to develop guidelines for medical prioritization, but most importantly tofacilitate integration of pharmacogenomics and to support pre-emptive pharmacogenomictesting. This may subsequently contribute towards significant cost-savings in the overallhealthcare expenditure in the participating countries, where pharmacogenomics implementationproves to be cost-effective.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Plos One. - 11 : 9 (2016), p. 1-19. -
További szerzők:	Dalabira, Eleni Kumuthini Judit Dzimiri, Nduna Balogh István (1972-) (molekuláris biológus, genetikus) Başak, Nazli Böhm, Ruwen Borg, Joseph Borgiani, Paola Bozina, Nada Bruckmueller, Henrike Burzynska, Beata Carracedo, Angel Cascorbi, Ingolf Deltas, Constantinos Dolzan, Vita Fenech, Anthony Grech, Godfrey Kasiulevicius, Vytautas Kádaši, Ludevít Kučinskas, Vaidutis Khusnutdinova, Elza Loukas, Yiannis L. Macek Jr., Milan Makukh, Halyna Mathijssen, Ron Mitropoulos, Konstantinos Mitropoulou, Christina Novelli, Giuseppe Papantoni, Ioanna Pavlovic, Sonja Saglio, Giuseppe Setric, Jadranka Stojiljkovic, Maja Stubbs, Andrew P. Squassina, Alessio Torres, Maria Turnovec, Marek van Schaik, Ron H. Voskarides, Konstantinos Wakil, Salma M. Werk, Anneke del Zompo, Maria Zukic, Branka Katsila, Theodora Lee, Ming Ta Michael Motsinger-Rief, Alison Mc Leod, Howard L. Van der Spek, Peter J. Patrinos, George P.
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: